The health-related quality of life in patients with Chagas disease: the state of the art

Igor Lucas Geraldo Izalino de Almeida, Luciano Fonseca Lemos de Oliveira, Pedro Henrique Scheidt Figueiredo, Rafael Dias de Brito Oliveira, Thayrine Rosa Damasceno, Whesley Tanor Silva, Lucas Frois Fernandes de Oliveira, Matheus Ribeiro Ávila, Vanessa Pereira Lima, Ana Thereza Chaves Lages, Mauro Felippe Felix Mediano, Manoel Otávio Costa Rocha and Henrique Silveira Costa

Chagas disease (CD) is a neglected tropical disease associated with poverty in which patients are surrounded by stigma. These factors can contribute to reducing health-related quality of life (HRQoL). Therefore, a broad discussion of HRQoL in the CD population is required. This study aimed to discuss the main findings of HRQoL in patients with CD, focusing on the association between sociodemographic and lifestyle factors, echo-cardiographic and functional determinants, and the effect of non-invasive interventions on HRQoL. A literature search of the MEDLINE, Web of Science, CINAHL, Scopus, and LILACS databases was performed with no data or language restrictions. Twenty-two articles were included in this meta-analysis. In general, HRQoL is worse in patients with CD than in healthy individuals, particularly in the presence of cardiovascular and/or gastrointestinal symptoms. Sex, age, functional class, level of physical activity, healthy habits, and medications received could affect HRQoL. Among the echo-cardiographic and functional determinants, decreased systolic function seems to negatively affect HRQoL. No association with the peak oxygen uptake was observed in the maximal tests. By contrast, well-tolerated field tests with submaximal intensities were associated with HRQoL. Both pharmaceutical care and exercise training have a positive effect on the HRQoL of patients with CD. Sensitivity and specificity analyses of echocardiography and functional determinants could help in identifying patients with a high likelihood of CD. In conclusion, assessment of HRQoL can provide important information about the health status of patients with CD, and its use in clinical practice is warranted.

Keywords: Chagas disease. Chagas cardiomyopathy. Quality of life.

INTRODUCTION

Chagas disease (CD) is an infection caused by the protozoan Trypanosoma cruzi and remains a public health problem in Latin American countries. According to the World Health Organization, the prevalence of CD is estimated at 6 million worldwide, and CD is responsible for 12,000 deaths per year.

In the chronic phase of the disease, patients may present with indeterminate, cardiac, digestive, or mixed forms. In the indeterminate form, the patient remains asymptomatic, with a normal electrocardiogram (ECG) or minor non-specific electrocardiographic abnormalities. Additional investigations using more sophisticated sensitive and sensitive complementary methods may reveal changes, such as a higher frequency of exercise-induced ventricular arrhythmias in the exercise test. Gastrointestinal involvement can be detected in the digestive form, marked by the presence of megaeosphagus and megaclin. In the cardiac form, patients can progress with symptoms of heart failure such as fatigue and dyspnea, as well as with...
cardiovascular abnormalities such as malignant arrhythmias and thromboembolism\textsuperscript{3}. However, patients can also be asymptomatic despite changes in their cardiac examination results. The cardiac form, denoted Chagas cardiomyopathy (ChC), may present with preserved cardiac function with segmental wall motion impairment until myocardial dilation with mainly left ventricular global systolic dysfunction develops\textsuperscript{6}. Dilated ChC is responsible for the higher morbidity and mortality of the disease\textsuperscript{3,6,7}. Finally, the mixed form presents with both cardiac and digestive impairments.

Regardless of the clinical form, interest in assessing the health-related quality of life (HRQoL) of patients with CD has increased in recent decades. Affected individuals are surrounded by stigma, depressive symptoms, social vulnerability, economic and sociodemographic disadvantages, and difficulty in accessing health services\textsuperscript{8-10}, which contributes to the neglected aspect of the disease. Therefore, the present study aimed to discuss the main findings related to HRQoL of patients with CD. Two previous reviews\textsuperscript{11,12} addressed the HRQoL of patients with CD; however, the present study focused on the sociodemographic, lifestyle, echocardiographic, and functional determinants in addition to HRQoL after non-invasive interventions in this population.

**SEARCH METHOD**

A narrative review using a structured search strategy was conducted to analyze the main findings regarding HRQoL in patients with CD. Potential studies were identified through a search of the Online Medical Literature Analysis and Retrieval System (MEDLINE), Cumulative Index for Nursing and Allied Health Literature (CINAHL), Web of Science, Scopus, Latin American and Caribbean Health Sciences Literature (LILACS), and Embase databases. The following strategy was used for the PubMed search: ((Chagas disease[Title/Abstract]) OR (Chagas cardiomyopathy[Title/Abstract]) OR (Chagas heart disease[Title/Abstract])) AND ((quality of life[Title/Abstract]) OR (health-related quality of life[Title/Abstract])), which was modified for each database. The search was independently conducted by three authors (ILA, RDBO, and TRD) from June to August 2021.

The inclusion criteria were studies that assessed HRQoL in patients with CD. There were no restrictions on the language or publication year. The exclusion criteria were 1) animal studies, 2) qualitative studies, 3) review studies, and 4) studies that evaluated HRQoL after surgical or invasive procedures.

The original search identified 1,125 articles, of which 797 were duplicates. After reading the titles, abstracts, and objectives, 306 participants were excluded. A total of 22 papers were included in the present review (Figure 1).

Among the included studies, five questionnaires were used: the Short-Form of Health Survey (SF-36)\textsuperscript{13}, World Health Organization Quality of Life Questionnaire (WHOQOL–Bref)\textsuperscript{14}, Minnesota Living with Heart Failure Questionnaire (MLwHFQ)\textsuperscript{15}, Assessment of...
Reduced HRQoL in the cardiac and digestive forms was also found in another study24. The authors reported that the cardiac form was associated with worse HRQoL in the WHOQOL–Bref when compared to the indeterminate form; however, the digestive form had the worst scores among the chronic forms. According to Santos-Filho et al.8, ChC without heart failure was independently associated with a worse score in the social relationship domain, whereas a mixed form with heart failure was associated with a worse score in the environment domain. More studies are needed to show that the HRQoL of patients with the digestive form is worse than that of patients with ChC; however, so far, it can be stated that both clinical forms have worse scores than patients with the indeterminate form.

Another study25 compared the HRQoL of patients with cardiac pacemakers with and without CD using the AQUAREL questionnaire. It was reported that pacemaker patients with CD had worse scores in the chest discomfort and arrhythmia domains than those without CD.

Finally, in a cohort of patients with CD26, all of whom had some degree of cardiac impairment, there was no difference in HRQoL assessed by the WHOQOL–Bref in all domains (physical, psychological, social relationships, and environment) between patients with non-Chagas cardiomyopathy, ChC without heart failure, and ChC with heart failure. These results suggest that HRQoL is worse in patients with heart disease, regardless of the etiology or presence of heart failure. In contrast, another study27, composed of a population sample with more compromised cardiac function, found that patients with ChC had lower perceived HRQoL in the SF-36 domains of physical functioning and role-emotional, compared to those with non-Chagas cardiomyopathy. Similarly, another study28 compared HRQoL using the Kansas City Cardiomyopathy Questionnaire in three groups of heart failure: ChC, ischemic, and non-ischemic. The authors demonstrated that patients with ChC had worse HRQoL than those with non-ischemic cardiomyopathy. However, there was no difference between the patients with ChC and those with ischemic cardiomyopathy. Given these conflicting results, more studies are needed to confirm whether Chagas etiology is a determinant of HRQoL in patients with heart disease.

ASSOCIATION BETWEEN HRQOL AND SOCIODEMOGRAPHIC OR LIFESTYLE FACTORS IN PATIENTS WITH CD

Sociodemographic and lifestyle factors can significantly affect the HRQoL of both healthy individuals and patients with CD. Four studies (Table 2) aimed to verify the association between these factors and HRQoL in patients with CD.

In a sample with several chronic forms of the disease (indeterminate, cardiac, and digestive), one study24 showed no difference in HRQoL assessed using the WHOQOL–Bref between men and women. However, two other studies22,23 that included a larger sample with the same chronic forms of the disease and used the same questionnaire showed different results. Ozaki et al.23 demonstrated that women had worse scores in the environment domain and were more likely to perceive worse HRQoL than men. Santos-Filho et al.8 also demonstrated that women were independently associated with worse HRQoL in the overall score as well as in the physical and psychological domains of the WHOQOL–Bref. Lower HRQoL in women has also been demonstrated in healthy populations29,30. Compared to men, women have more...
There was no difference in HRQoL among groups in the physical HRQoL SF-36 events; Abbreviations:

Vieira & al. 2015

Oliveira et al. 2011

Ozaki et al. 2011

Ozaki et al. 2017

Shen et al. 2018

Sanchez-Filho et al. 2018

Quintino et al. 2020

| Author and year | Sample characteristics | HRQoL questionnaire | Comparison among different clinical forms of Chagas disease/cardio pathies/healthy individuals |
|-----------------|------------------------|---------------------|--------------------------------------------------------------------------------|
| Oliveira et al. 2008 | n=139 cardiac pacemaker patients (40% male) with (n=77) and without (n=31) CD, and individuals with unknown serology (n=31). | AQUAREL | Patients with CD and cardiac pacemakers had worse scores in the chest discomfort (p=0.030) and arrhythmia (p=0.004) domains compared to non-Chagas patients with cardiac pacemakers. |
| Gontijo et al. 2009 | n=70 patients with CD; 68% female, mean age of 53 years, ranging from 27 to 79 years. NYHA and LVEF not reported. | WHOQOL-Bref | Patients with ChC had worse HRQoL in the psychological domains when compared to patients with CD and without heart disease (p=0.05). There was no difference in the other domains between the groups. |
| Oliveira et al. 2011 | n=146 individuals: 21 without CD (median 46 years (Q1–Q3: 28–71): 62% male; 100% with NYHA I, and 16% with abnormal echocardiography); 125 with Chagas disease (median 29 years (Q1–Q3: 25–68): 58% male; 82% with NYHA I, and 56% with abnormal echocardiography). | SF-36 and MLwHFQ | The HRQoL of patients with CD was worse in the physical functioning (p=0.011) and role-emotional (p=0.020) SF-36 domains when compared to non-Chagas disease patients. HRQoL was also worse in the group with CD assessed using the MLwHFQ (p=0.028). In patients with CD, the presence of cardiovascular symptoms was associated with poor HRQoL in the physical (OR=4.12) and mental (OR=2.69) component summary of the SF-36. The presence of cardiovascular symptoms was also associated with worse HRQoL in patients with CD when assessed using the MLwHFQ compared to individuals without CD (OR=3.11). |
| Ozaki et al. 2011 | n=110 patients with CD (49.09% with ChC: 26.36% with the indeterminate form, 12.73% with the digestive form, and 11.82% with the mixed form); 53% female; mean age of 51 years (ranging from 23 to 82 years). NYHA and LVEF not reported. | WHOQOL-Bref | In the physical domain, the HRQoL of patients in the indeterminate form was significantly better when compared to other clinical forms (p<0.0001). Regarding the social relationships domain, there was a significant difference between the indeterminate and cardiac forms (p<0.0389). Among those with the chronic phase of CD, those with the digestive form had lower HRQoL scores. |
| Pelegrino et al. 2011 | n=43 patients with ChC (62.8% male) and non-Chagas cardiomyopathy (n=59, 57.6% male). | SF-36 | Patients with ChC had worse HRQoL in the role-physical (p=0.002) and physical functioning (p=0.011) SF-36 domains when compared to non-Chagas cardiomyopathy. |
| Vieira et al. 2014 | n=16 patients with ChC (53.3±9.2 years, 43.8% female, NYHA I–III, LVEF 34.1±8.0%) and 16 with Chagas disease without cardiomyopathy (51.9±11.9 years; 50.0% female; NYHA I; LVEF 67.3±5.4%). | MLwHFQ | The group with ChC showed decreased HRQoL in the overall score (p=0.001) and in the physical (p=0.031) and role-emotional (p=0.001) domains of the MLwHFQ when compared to patients with Chagas disease without cardiomyopathy. |
| Ozaki et al. 2015 | n=202 patients with Chagas disease (66.8% with ChC, 11.4% with the digestive form, and 21.8% with the indeterminate form); 53.96% female; 68.1% aged between 25 and 59 years. NYHA and LVEF not reported. | WHOQOL–Bref | The variables that were associated with worse scores in the physical domain were the digestive and cardiac forms (OR=3.33 and OR=2.93 times more likely, respectively, than the indeterminate form). In the psychological domain, the associated variables were the digestive and cardiac forms (OR=3.33 and OR=2.93 times more likely, respectively, than the indeterminate form). In the social relationships domain, the associated variables were the digestive and cardiac forms (OR=3.63 and OR=2.17 times more likely, respectively, than the indeterminate form. |
| Shen et al. 2017 | n=189 patients with dilated ChC (59.6±10.7 years; 66.2% male, NYHA I to III, LVEF 28.5±6.2%); 1101 patients with non-ischemic cardiomyopathy (61.1±12.5 years; 69.0% male, NYHA I to IV; LVEF 27.1±6.3%); 848 patients with ischemic cardiomyopathy (65.8±10.1 years; 78.3% male; NYHA I to IV; LVEF 28.5±6.1%). | Kansas City Cardiomyopathy Questionnaire | Patients with ChC and reduced LVEF have a worse HRQoL than patients with non-ischemic cardiomyopathy (p=0.006). There was no significant difference between patients with dilated ChC and patients with ischemic cardiomyopathy (p=0.255). |
| Santos-Filho et al. 2018 | n=361 patients (indeterminate form (n=97), ChC without heart failure (n=157), ChC with heart failure (n=94), digestive (n=13), cardiodigestive without heart failure (n=38) and cardiodigestive with heart failure (n=7)); 60.7±10.8 years; 56.3% female; NYHA I to IV; LVEF=57.9±13.9%. | WHOQOL–Bref | In the social relationship domain, the ChC without heart failure was independently associated with worse HRQoL (p<0.02). In the environment domain, the cardiodigestive form with heart failure was associated with worse HRQoL (p=0.01). |
| Quintino et al. 2020 | n=625 patients (65.8% female, 56.7±12.2 years) with non-chagasic cardiomyopathy, ChC without heart failure, and ChC with heart failure. | WHOQOL–Bref | There was no difference in HRQoL among groups in the physical (p=0.177), psychological (p=0.304), social relations (p=0.819) and environment (p=0.959) domains. |

Abbreviations: ChC: Chagas cardiomyopathy; CD: Chagas disease; HRQoL: health-related quality of life; WHOQOL–Bref: World Health Organization Quality of Life Questionnaire; SF-36: Short form of Health Survey; MLwHFQ: Minnesota Living with Heart Failure Questionnaire; AQUAREL: assessment of quality of life and related events; NYHA: New York Heart Association; LVEF: left ventricular ejection fraction; Q1–Q3: interquartile range; OR: odds ratio.
non-life-threatening diseases as well as a higher prevalence of mental disorders such as depression\textsuperscript{35}. In CD, female sex was also associated with depressive symptoms\textsuperscript{8}. Thus, we believe that female sex is associated with worse HRQoL in patients with CD.

Santos-Filho et al.\textsuperscript{4} also demonstrated that a worse New York Heart Association (NYHA) functional class, decreased sleep duration, lower schooling, decreased physical activity levels, smoking, decreased income per capita, and residents by domicile were independently associated with poor HRQoL. In another study\textsuperscript{36}, increased age, use of angiotensin-converting enzyme inhibitors, history of acute myocardial infarction, and not using angiotensin receptor blockers were also associated with poor HRQoL in patients with CD.

Age is associated with physical and environmental domains, and functional impairment is common with increasing age\textsuperscript{31}, which negatively affects HRQoL. A history of a previous acute myocardial infarction was associated with worse scores in the social relationship domain, which may be explained by a lower perception of emotional support and greater fear of social interactions after a myocardial infarction\textsuperscript{32}. Regarding the medications received, the use of angiotensin-converting enzyme inhibitors was associated with worse HRQoL in the physical domain. A common adverse effect of angiotensin-converting enzyme inhibitor is cough\textsuperscript{33}, which may impact the physical domain of HRQoL, especially at high doses. In contrast, the use of angiotensin receptor blockers was associated with a better HRQoL in patients with CD. Angiotensin receptor blockers have a low incidence of adverse effects and are associated with better HRQoL than other therapies for patients with arterial hypertension and/or heart failure\textsuperscript{34}.

### ASSOCIATION BETWEEN HRQoL AND FUNCTIONAL VARIABLES, ECHOCARDIOGRAPHIC PARAMETERS, OR DISABILITIES

Seven studies verified the association between HRQoL and functional capacity, disability, and/or echocardiography findings (Table 3).

Systolic dysfunction, assessed by left ventricular ejection fraction (LVEF), is a well-established prognostic marker in the CD population\textsuperscript{35-37}, and two studies\textsuperscript{38,39} have verified the association between HRQoL and cardiac function. One study in patients with ChC and heart failure (n=55, LVEF <45%) demonstrated a weak but significant correlation between HRQoL, as assessed by the MLwHFQ and LVEF. According to the authors, the lower the LVEF, the worse the HRQoL of the patient. Ávila et al.\textsuperscript{30} showed an association between HRQoL and systolic dysfunction in patients with ChC. The authors stratified the sample into groups according to systolic dysfunction and preserved cardiac function. The groups with systolic dysfunction had worse QoL in the domains of physical functioning, physical role functioning, and general health perception. In addition, the accuracy of the SF-36 in identifying patients with systolic dysfunction was demonstrated. The physical component of the SF-36 showed good efficacy in identifying these patients. A score of <46 points was the optimal cutoff point for diagnostic accuracy, with a positive predictive value of 91%. Therefore, the physical component of SF-36 can be used as a risk stratification and screening tool for patients with ChC, especially when echocardiography is scarcely available.

Functional capacity, assessed by both peak oxygen uptake (VO2peak) and field tests, has clinical and prognostic importance.
TABLE 3: Association between HRQoL and echocardiographic, functional, and disabilities parameters (n=6).

| Author and year | Sample characteristics | HRQoL questionnaire | Association with functional and echocardiographic parameters |
|-----------------|------------------------|---------------------|------------------------------------------------------------|
| Dourado et al. 2006 | n=61 patients with ChC and heart failure, (mean age: 50±14 years; 71% male; NYHA 1 to IV; LVEF=33.5±12%). | MLwHFQ | The 6MWT distance was correlated with the MLwHFQ total score (r=-0.4; p<0.001), physical dimension (r=-0.42; p=0.001) and emotional dimension (r=-0.33; p=0.008) domains. |
| Ritt et al. 2013 | n=55 patients with ChC and LVEF<45% (NYHA II to IV, LVEF=27.6±6.6%). | MLwHFQ | The HRQoL was correlated with VO2peak (r=-0.301, p<0.02), 6MWT distance (r=-0.375, p<0.007), and LVEF (r=-0.282, p<0.03). These variables explained 30% of the variation in the MLwHFQ. |
| Souza et al. 2013 | n=21 patients with Chagas disease after stroke (50±13.9 years; 57% male; NYHA and LVEF not reported). | WHOQOL–Bref | There was no correlation between disability, assessed by Modified Rankin Stroke Scale, with any of the WHOQOL–Bref domains [physical (r=0.207; p=0.410), psychological (r=0.017; p=0.946), environment (r=0.511; p=0.830), and social relationship (r=0.229; p=0.360)]. |
| Costa et al. 2014 | n=35 patients with ChC; mean age: 47.1±8.2 years; 65.7% male; NYHA I to III; median LVEF=59% (interquartile range from 41 to 46%). | SF-36 and MLHFQ | The ISWT distance was correlated with the MLwHFQ total score (r=-0.460; p=0.06), and some SF-36 domains [physical functioning (r=0.435; p=0.009), role-physical functioning (r=0.447; p=0.008), and mental health (r=0.430; p=0.011)]. The VO2peak was correlated only with the physical functioning domain of the SF-36 (r=0.383; p=0.025). There was no correlation between VO2peak and MLwHFQ score (r=-0.337; p=0.055). |
| Chambeia et al. 2017 | n=53 patients with ChC; mean age: 60±12 years; 48.8% female; NYHA I to III; LVEF=35.1±11.1%. | SF-36 and MLHFQ | There was a significant correlation between the 6MWT distance and MLwHFQ total score (r=-0.54; p=0.002) and some SF-36 domains [physical functioning (r=0.46; p=0.008), role-physical functioning (r=0.37; p=0.04), and bodily pain (r=0.43; p=0.014)]. |
| Ávila et al. 2021 | n=75 patients with ChC; mean age: 49 years (95% CI: 47 to 51); 46% male; NYHA I to III; LVEF=44% (95% CI: 41 to 48%). | SF-36 | Patients with systolic dysfunction have a worse HRQoL in the physical functioning (p<0.001), role-physical functioning (p=0.041), and general health perception (p=0.013) domains when compared to those who have preserved systolic function. The best cut-off points in identifying patients with systolic dysfunction were scores ≥46 and ≤54 in the physical and mental components of the SF-36, respectively. |

**Abbreviations:** ChC: Chagas cardiomyopathy; HRQoL: health-related quality of life; WHOQOL–Bref: World Health Organization Quality of Life Questionnaire; NYHA: New York Heart Association; LVEF: left ventricular ejection fraction; SF-36: Short-Form Health Survey; MLwHFQ: Minnesota Living with Heart Failure Questionnaire; VO2peak: peak oxygen uptake; 6MWT: six-minute walk test; ISWT: incremental shuttle walk test.

in patients with ChC. Two studies included in this review verified the association between VO2peak and HRQoL, assessed using the MLwHFQ and SF-36. One study with a sample of patients with both systolic dysfunction and preserved cardiac function found no correlation between VO2peak and MLwHFQ scores. The authors also used the SF-36 questionnaire and only the physical functioning domain showed a significant correlation. Another study in patients with ChC and heart failure found a weak but significant correlation between VO2peak and MLwHFQ score. This finding suggests that VO2peak and maximal functional capacity may not reflect HRQoL in patients with ChC. We hypothesized that HRQoL is more strongly associated with daily activities, usually performed at a submaximal level. Therefore, field tests can be useful tools for investigating patients’ perceptions of their health.

Two field tests have already been applied in patients with ChC for functional assessment: the six-minute walk test (6MWT) and incremental shuttle walk test (ISWT). The 6MWT is a field test that evaluates functional capacity by the distance covered in six minutes. In patients with preserved cardiac function, the 6MWT distance was not correlated with the presence of depressive symptoms. In patients with ChC and systolic dysfunction, the 6MWT distance was correlated with the MLwHFQ total score and with the SF-36 domains of physical functioning, role-physical functioning, and bodily pain. It has also been shown that, among functional variables, the 6MWT distance was the only determinant of HRQoL. A 10-m increase in the 6MWT distance is associated with a reduction of 0.7 points in the MLwHFQ score.

The ISWT is a symptom-limited field test with progressive loads and 12 levels of intensity, where the functional capacity is evaluated by the walked distance. In patients with ChC, only one study verified the association between ISWT distance and HRQoL using both the 6MWT and MLwHFQ. The authors demonstrated that ISWT distance was correlated with MLwHFQ total score and the physical functioning, role-physical functioning, and mental health domains of the SF-36. The results regarding the association between HRQoL and the field tests corroborate our hypothesis that submaximal tests are more representative of HRQoL than maximal tests.

Regarding disability, one study verified the association between HRQoL using the WHOQOL–BREF and the degree of disability using the Modified Rankin Stroke Scale in patients with CD after stroke. It has been shown that cerebrovascular events are frequent in patients with CD, and these may be the first clinical manifestation of the disease. However, the authors found no association between disability and the WHOQOL–BREF domains. Disability was associated with functional performance, whereas HRQoL was associated with depressive symptoms.

**HRQOL ASSESSMENT IN LONGITUDINAL STUDIES**

Recent studies have highlighted the importance of assessing HRQoL in clinical trials as an effective tool to detect patient-reported changes. Thus, HRQoL has the potential to identify improvements in health from proposed interventions and can be used as a valuable prognostic marker.
Six longitudinal studies\textsuperscript{57-62} assessed the HRQoL of patients with ChC (Table 4). Five of them\textsuperscript{57-60,62} evaluated the effects of physical interventions or drug therapies on HRQoL, and one observational study\textsuperscript{61} verified the prognostic value of HRQoL in patients with ChC.

The reassessment of HRQoL after drug therapy was verified in two studies. Chambela et al.\textsuperscript{57} found that the group of patients with ChC and heart failure who received optimized drug therapy (n=40) showed a significant improvement in many domains of the SF-36 and in the total score of the MLwHFQ compared to (n=41). Therefore, the results suggest that both the SF-36 and MLwHFQ may be sensitive in identifying improvements in the health perception of patients with ChC and heart failure after drug therapy. Another study\textsuperscript{62} that verified HRQoL after pharmacological treatments was carried out in two stages. First, all patients with ChC (n=39) were administered enalapril and spironolactone. Subsequently, there was a significant improvement in their SF-36 total scores, including in the physical functioning, role-physical functioning, bodily pain, general health perceptions, and mental health domains. Second, patients in the

**TABLE 4:** The use of HRQoL assessment questionnaires in longitudinal studies (n=6).

| Author and year | Sample characteristics | HRQoL questionnaire | Follow-up | Results |
|-----------------|------------------------|---------------------|-----------|---------|
| Botoni et al. 2007 | n=39 patients with ChC; 47.8±10.4 years; 71% male; NYHA I to III; FEVE 43.2±14.5%. Groups were stratified into control group (received enalapril and spironolactone, n=20) and intervention group (received carvedilol after enalapril and spironolactone, n=19). | SF-36 | Drug therapy (use of carvedilol after renin-angiotensin system inhibition) | Optimization of RAS inhibition was associated with improvements in the SF-36 total score (p<0.0003), including in the physical functioning (p=0.046), role-physical functioning (p=0.002), bodily pain (p=0.021), general health perceptions (p<0.001), and mental health (p=0.033) domains. The subsequent use of carvedilol did not improve any SF-36 domain. |
| Lima et al. 2010 | n=40 patients with dilated ChC, stratified in an inactive control group (n=19, 36% female, NYHA I to II, LVEF=37.0±7.6%) and an exercise training group (n=21, 48% female, NYHA I to II, LVEF=35.7±8.1%). | SF-36 | Exercise training (12 weeks, 3 times per week, at moderate intensity) | Exercise training improved the intergroup HRQoL in the vitality (p=0.013), role-emotional (p=0.012), and mental health (p=0.013) domains of the SF-36. |
| Mediano et al. 2016 | n=12 patients with ChC and heart failure (single group, 56.1±13.8 years, 75% female; NYHA I to III; LVEF=31.9±7.7%). | MLwHFQ | Exercise training (8 months, 3 times per week, 60 minutes per session, at moderate intensity) | Patients with right ventricular dysfunction at baseline exhibited improvements in MLwHFQ total score (p=0.009). Improvements in MLwHFQ were not observed among those without right ventricular dysfunction. |
| Mediano et al. 2017 | n=12 patients with ChC and heart failure (single group, 56.1±13.8 years, 75% female; NYHA I to III; LVEF=31.9±7.7%). | SF-36 | Exercise training (6 months, 3 times per week, 60 minutes per session, at moderate intensity) | Exercise training led to improvements in the physical functioning (p=0.003), role-physical functioning (p=0.03), and bodily pain (p=0.02) SF-36 domains, as well as in the physical component summary (p=0.001) domain. Patients with right ventricular dysfunction demonstrated significant improvements in the physical functioning (p=0.001), bodily pain (p=0.02), and vitality (p=0.03) SF-36 domains, and in the physical component summary (p=0.001). Patients with preserved right ventricular function showed significant improvements only in the physical component summary (p=0.002). |
| Costa et al. 2018 | n=75 patients with ChC (with and without systolic dysfunction), 48.4±8.0 years; 39% female, median LVEF=41.0% (Q1-Q3 35.0–53.5); NYHA I to III. | SF-36 | Observational (six years of follow-up) | After the follow-up period, the general health (p=0.047) and social functioning (p=0.026) SF-36 domains, as well as the mental component summary (p=0.043), were significantly different between the groups with and without adverse cardiovascular events. In the final multivariate Cox regression model, LVEF (HR 0.94, 95% CI from 0.90 to 0.98, p=0.007) and the mental component summary of the SF-36 (HR 0.98, 95% CI from 0.94 to 1.00, p=0.047), remained as independent predictors of adverse cardiovascular outcome in patients with ChC. |
| Chambela et al. 2020 | n=81 patients with ChC and heart failure, 61±11 years, 52% female, NYHA I to III, LVEF=36.0±9.9%. Groups were stratified into standard care (n=41) and pharmaceutical care (n=40). | SF-36 and MLwHFQ | Drug therapy (one year of follow-up) | When compared with the standard care group, patients under drug therapy, after one year, showed improvements in the physical functioning (p<0.001), role-physical functioning (p=0.01), general health perceptions (p=0.001), vitality (p=0.003), social functioning (p=0.002), and mental health (p=0.006) domains. Improvement in HRQoL, as assessed by the MLwHFQ, was also higher in those under drug therapy compared to those under standard care after one year (p<0.001). |

**Abbreviations:** ChC: Chagas cardiomyopathy; HRQoL: health-related quality of life; WHOQOL-Bref: World Health Organization Quality of Life Questionnaire, SF-36: Short form of Health Survey; MLwHFQ: Minnesota Living with Heart Failure Questionnaire; NYHA: New York Heart Association; LVEF: left ventricular ejection fraction; 95% CI: 95% confidence interval; HR: hazard ratio.
The effects of exercise training on HRQoL were demonstrated in three studies, all of which included patients with systolic dysfunction. One study, which applied a three-month moderate-intensity intervention, showed improvement in the vitality, role-emotional, and mental health domains of the SF-36 in the exercise group when compared to the inactive group. The improvements in the mental and emotional factors were greater than in the physical factors, despite the improvement in the functional capacity. The authors highlighted that interpersonal contact during the exercise program was important for increasing well-being and improving the psychosocial aspects. Another study showed improvements in the domains of physical functioning, role-physical functioning, and bodily pain, as well as in the physical component summary, after 8 months of an exercise intervention. The study consisted of a single-arm intervention that included 12 patients with ChC and heart failure. In a reassessment analysis including the same patients, the authors demonstrated an improvement in the total MlwHfQ score compared to patients with right ventricular dysfunction. The beneficial changes in HRQoL also accompanied the clinical changes in these patients, and individuals with the greatest severity of cardiac impairment obtained the most substantial benefits in cardiac hemodynamics, respiratory strength, and HRQoL.

Finally, in a study of 75 patients with ChC, Costa et al. verified the prognostic value of HRQoL in predicting adverse cerebrovascular events. After six years of follow-up, the mental component of the SF-36 together with LVEF remained an independent predictor of adverse events. The physical component did not show significant prognostic value; however, the sample was predominantly composed of patients with preserved functional class, and studies with patients with functional impairment should be conducted. Therefore, the findings suggest that HRQoL, especially the mental aspects, should be used in clinical follow-ups, since the patient can be aware of the progression of the disease.

**FINAL CONSIDERATIONS**

The results of the included studies suggest that 1) HRQoL is worse in patients with CD than in healthy individuals; 2) the presence of cardiovascular and gastrointestinal symptoms are responsible for worse HRQoL scores in terms of both physical and mental aspects; 3) the HRQoL in patients with ChC compared to those with other heart diseases is still poorly understood; 4) female sex is associated with worse HRQoL; 5) other factors, including age, functional class, level of physical activity, healthy habits, and medications, can affect the HRQoL of patients; 6) HRQoL is related to systolic function; 7) functional capacity assessed by VO2peak may not reflect the HRQoL in ChC; 8) field tests may be associated with HRQoL; 9) drug therapy, in general, has a positive effect on the HRQoL of patients with ChC; 10) exercise training can also positively impact HRQoL in both physical and emotional aspects; and 11) HRQoL, especially the mental component, can be a prognostic marker in patients with ChC.

**ACKNOWLEDGMENTS**

None.

**REFERENCES**

1. Dias JC, Ramos Jr AN, Gontijo ED, Luquetti A, Shikanai-Yasuda MA, Coura JR, et al. 2 nd Brazilian Consensus on Chagas Disease, 2015. Rev Soc Bras Med Trop. 2016;49(Suppl 1):3-60.

2. Pan American Health Organization. Chagas disease [Internet]. [cited 2022 January 16]. Available from: http://www.paho.org/en/topics/chagas-disease.

3. Rocha MOC, Teixeira MM, Ribeiro AL. An update on the management of Chagas cardiomyopathy. Expert Rev Anti Infect Ther. 2007; 5(4):727-43.

4. Ribeiro AL, Rocha MO. Indeterminate form of Chagas’ disease: considerations about diagnosis and prognosis. Rev Soc Bras Med Trop. 1998;31(3):301-14.

5. Costa HS, Nunes MCP, de Souza AC, Lima MMO, Carneiro RB, de Sousa GR, et al. Exercise-induced ventricular arrhythmias and vagal dysfunction in Chagas disease patients with no apparent cardiac involvement. Rev Soc Bras Med Trop. 2015; 48(2):175-80.

6. Nunes MCP, Beaton A, Acquatella H, Bern C, Bolger AF, Echeverria LE, et al. Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. Circulation. 2018; 138(12):e169-e209.

7. Botoni FA, Ribeiro ALP, Marinho CC, Lima MMO, Nunes MCP, Rocha MOC. Treatment of Chagas cardiomyopathy. Biomed Res Int. 2013;2013:849504.

8. Santos-Filho JCL, Vieira MC, Xavier IGG, Maciel ER, Rodrigues Jr LF, Curvo EOV, et al. Quality of life and associated factors in patients with chronic Chagas disease. Trop Med Int Health. 2018;23(11):1213-22.

9. Silva WT, Avila MR, de Oliveira LFF, Figueiredo PHS, Lima VP, Bastone AC, et al. Prevalence and determinants of depressive symptoms in patients with Chagas cardiomyopathy and predominantly preserved cardiac function. Rev Soc Bras Med Trop. 2020;53:e20200123.

10. Ventura-Garcia L, Roura M, Pell C, Posada E, Gascón J, Aldasoro E, et al. Socio-cultural aspects of Chagas disease: a systematic review of qualitative research. PLoS Negl Trop Dis. 2013;7(9):e2410.

11. Sousa GR, Costa HS, Souza AC, Nunes MCP, Lima MMO, Rocha MOC. Health-related quality of life in patients with Chagas disease: a review of the evidence. Rev Soc Bras Med Trop. 2015;48(2):121-8.

12. Baldoni NR, Quintino ND, Alves LCS, Oliveira CDL, Sabino EC, Ribeiro ALP, et al. Quality of life in patients with Chagas disease and the instrument used: an integrative review. Rev Inst Med Trop Sao Paulo. 2021;63:e46.

13. Ware JE, Jr. and Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-83.

14. Skewington SM, Lofty M, O’Connell KA, WHOQOL Group. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13(2):299-310.

15. Carvalho VO, Guimarães GV, Carrara D, Bacal F, Bocchi EA. Validation of specific quality-of-life questionnaire -AQUAREL - for pacemaker patients. Arq Bras Cardiol. 2009;93(2):e2410.

16. Oliveira BG, Melendez JG, Ciconelli RM, Rincón LG, Torres AAS, Sousa GR, et al. Socio-cultural aspects of Chagas disease: a systematic review of qualitative research. PLoS Negl Trop Dis. 2013;7(9):e2410.

17. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245-55.
18. Oliveira BG, Abreu MNS, Abreu CDG, Rocha MOC, Ribeiro AL. Health-related quality of life in patients with Chagas disease. Rev Soc Bras Med Trop. 2011; 44(2):150-6.

19. Gontijo ED, Guimarães TN, Magnani C, Paixão GM, Dupin S, Paixão LM. Qualidade de vida dos portadores de doença de Chagas. Rev Med Minas Gerais. 2009; 19(4):281-5.

20. Vieira FC, de Melo Marinho PE, Brandao DC, Silva OB. Respiratory muscle strength, the six-minute walk test and quality of life in Chagas cardiomyopathy. Physiother Res Int. 2014;19(1):8-15.

21. Costa HS, Lima MMO, Costa FSM, Chaves AT, Nunes MCP, Figueiredo PHs, et al. Reduced functional capacity in patients with Chagas disease: a systematic review with meta-analysis. Rev Soc Bras Med Trop. 2018;51(4):421-6.

22. Blasco-Hernandez T, Garcia-San Miguel L, Navaza B, Navarro M, Benito A. Knowledge and experiences of Chagas disease in Bolivian women living in Spain: a qualitative study. Glob Health Action. 2016;9:30201.

23. Ozaki Y, Dias ELF, Almeida EAd, Guarienio ME. Quality of life in adults and older adults with Chagas disease. Rev Ciênc Méd. 2015;24(3):93-104.

24. Ozaki Y, Guarienio ME, de Almeida EA. Quality of life and depressive symptoms in Chagas disease patients. Qual Life Res. 2011; 20(1):133-8.

25. Oliveira BG, Velasquez-Melendez G, Rincon LG, Ciconelli RM, Sousa LA, Ribeiro AL. Health-related quality of life in Brazilian pacemaker patients. Pacing Clin Electrophysiol. 2008;31(9):1178-83.

26. Quintino ND, Sabino EC, da Silva JLP, Ribeiro ALP, Ferreira AM, Davi GL, Oliveira CDLO, et al. Factors associated with quality of life in patients with Chagas disease: SaMi-Trop project. PLoS Negl Trop Dis. 2020;14(5):e0008144.

27. Pelegrino VM, Dantas RAS, Ciol MA, Clark AM, Rossi LA, Simoes MV. Health-related quality of life in Brazilian outpatients with Chagas and non-Chagas cardiomyopathy. Heart Lung. 2011;40(3):e25-31.

28. Shen L, Ramirez F, Martinez F, Bodanese LC, Echeverria LE, Gomez EA, et al. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circ Heart Fail. 2017;10(11):e004361.

29. Cherepanov D, Palta M, Fryback DG, Robert SA. Gender differences in health-related quality-of-life are partly explained by sociodemographic and socioeconomic variation between adult men and women in the US: evidence from four US nationally representative data sets. Qual Life Res. 2010;19(8):1115-24.

30. Hajian-Tilaki K, Heidari B, Hajian-Tilaki A. Are Gender Differences in Health-related Quality of Life Attributable to Sociodemographic Characteristics and Chronic Disease Conditions in Elderly People? Int J Prev Med. 2017;8:95.

31. Brown RT, Diaz-Ramirez LG, Boscardin WJ, Lee SJ, Steinman MA. Functional Impairment and Decline in Middle Age: A Cohort Study. Ann Intern Med. 2017;167(11):761-8.

32. Welin CL, Rosengren A, Wilhelmsen LW. Social relationships and myocardial infarction: a case-control study. J Cardiovasc Risk. 1996;3(2):183-90.

33. Parish RC, Miller LJ. Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update. Drug Saf. 1992;7(1):14-31.

34. Weber MA. Angiotensin II receptor blockers for hypertension and heart failure: quality of life and outcomes. Manag Care Interface. 2005;18(2):47-54.

35. Nunes MCP, Carmo AAL, Rocha MOC, Ribeiro AL. Mortality prediction in Chagas heart disease. Expert Rev Cardiovasc Ther. 2012;10(9):1173-84.

36. Ribeiro AL, Nunes MP, Teixeira MM, Rocha MOC. Diagnosis and management of Chagas disease and cardiomyopathy. Nat Rev Cardiol. 2012;9(10):576-89.

37. Rassi Jr A, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation. 2007;115(9):1101-8.

38. Ritt LE, Carvalho AC, Feitosa GS, Pinho-Filho JA, Andrade MVS, Feitosa-Filho GS, et al. Cardiopulmonary exercise and 6-min walk tests as predictors of quality of life and long-term mortality among patients with heart failure due to Chagas disease. Int J Cardiol. 2013;168(4):4584-5.

39. Avila MR, Figueiredo PHS, Lima VP, Silva WT, Vianna MVA, Fernandes LHC, et al. Accuracy of health-related quality of life in identifying systolic dysfunction in patients with Chagas cardiomyopathy. Trop Med Int Health. 2021;26(8):936-42.

40. Costa HS, Lima MMO, Figueiredo PHs, Lima VP, Ávila MR, de Menezes KKP, et al. Exercise tests in Chagas cardiomyopathy: an overview of functional evaluation, prognostic significance, and current challenges. Rev Soc Bras Med Trop. 2020;53:e20200100.

41. Costa HS, Alves RL, da Silva SA, Alencar MCN, Nunes MCP, Lima MMO, et al. Assessment of Functional Capacity in Chagas Heart Disease by Incremental Shuttle Walk Test and its Relation to Quality-of-Life. Int J Prev Med. 2014;5(2):152-8.

42. Nascimento BR, Lima MMO, Nunes MCP, de Alencar MCN, Costa HS, Pinto Filho MM, et al. Effects of exercise training on heart rate variability in Chagas heart disease. Arq Bras Cardiol. 2014;103(3):201-8.

43. Costa HS, Lima MMO, Alencar MCN, Sousa GR, Figueiredo PHs, Nunes MCP, et al. Prediction of peak oxygen uptake in patients with Chagas heart disease: Value of the Six-minute Walk Test. Int J Cardiol. 2017;228:385-7.

44. Costa HS, Lima MMO, de Souza GR, de Souza AC, Alencar MCN, Nunes MCP, et al. Functional capacity and risk stratification by the Six-minute Walk Test in Chagas heart disease: comparison with Cardiopulmonary Exercise Testing. Int J Cardiol. 2014;177(2):661-3.

45. Sousa L, Botoni FA, Britto RR, Rocha MOC, Teixeira Jr AL, Teixeira Jr MM, et al. Six-minute walk test in Chagas cardiomyopathy. Int J Cardiol. 2008;125(1):139-41.

46. Alves R, Lima MM, Fonseca C, dos Reis R, Figueiredo PH, Costa H, et al. Peak oxygen uptake during the incremental shuttle walk test in a predominantly female population with Chagas heart disease. Eur J Phys Rehabil Med. 2016;52(1):20-7.

47. Avila MR, Figueiredo PHs, Lima VP, de Oliveira LFL, de Oliveira LFF, Silva WT, et al. The prognostic value of the Incremental Shuttle Walk Test in Chagas cardiomyopathy. Disabil Rehabil. 2021:1-6.

48. Costa HS, Lima MMO, Lage SM, da Costa FSM, Figueiredo PHs, Rocha MOC. Six-minute walk test and incremental shuttle walk test in the evaluation of functional capacity in Chagas heart disease. J Exerc Rehabil. 2018;14(5):844-50.

49. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-7.

50. Chambela MC, Mediano MFF, Ferreira RR, Japiassú AM, Waghabi MC, da Silva GMS, et al. Correlation of 6-min walk test with left ventricular function and quality of life in heart failure due to Chagas disease. Trop Med Intern Health. 2017;22(10):1314-21.

51. Dourado KC, Bestetti RB, Cordeiro JA, Theodoropoulos TA. Assessment of quality of life in patients with chronic heart failure secondary to Chagas' cardiomyopathy. Int J Cardiol. 2006;108(3):412-3.

52. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax. 1992;47(12):1019-24.
53. de Souza AC, Rocha MOC, Teixeira AL, Dias Júnior JO, de Sousa LAP, Nunes MCP. Depressive symptoms and disability in chagasic stroke patients: impact on functionality and quality of life. J Neurol Sci. 2013;324(1-2):34-7.

54. Carod-Artal FJ, Gascon J. Chagas disease and stroke. Lancet Neurol. 2010; 9(5):533-42.

55. Pokharel Y, Khariton Y, Tang Y, Nassif ME, Chan PS, Arnold SV, et al. Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Cardiol. 2017;2(12):1315-21.

56. Del Buono MG, Arena R, Borlaug BA, Carbone S, Canada JM, Kirkman DL, et al. Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(17):2209-25.

57. Chambela MDC, Mediano MFF, Carneiro FM, Ferreira RR, Waghabi MC, Mendes VG, et al. Impact of pharmaceutical care on the quality of life of patients with heart failure due to chronic Chagas disease: Randomized clinical trial. Br J Clin Pharmacol. 2020;86(1):143-54.

58. Mediano MFF, Mendes FdeSNS, Pinto VLM, da Silva GMS, da Silva PS, Carneiro FM, et al. Cardiac rehabilitation program in patients with Chagas heart failure: a single-arm pilot study. Rev Soc Bras Med Trop. 2016;49(3):319-28.

59. Mediano MFF, Mendes FdeSNS, Pinto VLM, da Silva PS, Hasslocher-Moreno AM, de Sousa AS. Reassessment of quality of life domains in patients with compensated Chagas heart failure after participating in a cardiac rehabilitation program. Rev Soc Bras Med Trop. 2017;50(3):404-7.

60. Lima MMO, Rocha MOC, Nunes MCP, Sousa L, Costa HS, Alencar MCN, et al. A randomized trial of the effects of exercise training in Chagas cardiomyopathy. Eur J Heart Fail. 2010;12(8):866-73.

61. Costa HS, Lima MMO, Figueiredo PHS, Chaves AT, Nunes, MCP, Rocha MOC. The prognostic value of health-related quality of life in patients with Chagas heart disease. Qual Life Res. 2019;28(1):67-72.

62. Botoni FA, Poole-Wilson PA, Ribeiro ALP, Okonko DO, Oliveira BMR, Pinto AS, et al. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J. 2007;153(4):544.e1-8.